Active	Status	Sponsor type	Region	Phase	Filter
1 Active 2 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
gersizangitide (AXT107) / Asclepix
DISCOVER, NCT05859776: Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)	Active, not recruiting	1/2	15	US	AXT107 Low Dose, Gersizangatide, AXT107 Mid Dose, AXT107 High Dose	AsclepiX Therapeutics, Inc.	Neovascular Age-related Macular Degeneration	03/25	05/25